Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogenic Islet Cells for Type 1 Diabetes
NCT00160732Phase 2Active, not recruiting
- Sponsor
- University of Chicago
- Start
- Oct 2003
- Primary completion
- Oct 2030
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
A Phase 2 trial of donislecel in type 1 diabetes mellitus (T1D), sponsored by University of Chicago. Started Oct 2003; status: active, not recruiting.
02
Drugs
donislecel
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT00160732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00160732.